50% off Premium Yearly
It has no growth.
Stock price when the opinion was issued
As of Oct 16, 2026. Market Open.
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.
Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.
Build your watch list
Sign in to track investmentsyou care about
Capital Wealth Planning
Capital Area Planning Group
New Edge Capital
Odyssey Capital Advisors
RN Croft Financial Group
It has no growth.